CD274 and non-small cell lung carcinoma: The last decade has shown impressive clinical results for pembrolizumab as first-line treatment, monotherapy and neoadjuvant therapy for patients with PD-L1-expressing NSCLC, melanoma, and advanced gastric cancer who benefit from prolonged OS, manageable side effects and durable responses (91–95).